TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23650412
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with sequential trastuzumab (arm B)
Study: 25605861
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (arm A)
Study: 27363518
Drug: Fatty fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fatty fish (750 g/week)
Study: 27363518
Drug: Lean fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lean fish (750 g/week)
Study: 26630617
Drug: 0.1% hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% hyaluronate ophthalmic solution
Study: 21977856
Drug: Liandou Qingmai
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liandou Qingmai Recipe (treatment group, n = 45)
Study: 21977856
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (control group, n = 56)
Study: 20209464
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g GPLC
Study: 20209464
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g GPLC
Study: 16549460
Drug: Cinnamon supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamon supplementation (1.5 g/d)
Study: 15327724
Drug: Cognitive linguistic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive linguistic treatment
Study: 12949287
Drug: Northstar Iontophoretic
Normalized name: Sumatriptan Iontophoretic Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Northstar Iontophoretic Drug Delivery System (IDDS) with lidocaine (100 mg of 10%) and epinephrine (1.05 mg of 1:10,000)
Study: 10950829
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 7.5% dextrose in healthy adults
Study: 10950829
Drug: Insulin deficiency
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin deficiency in young adults with IDDM
Study: 1550697
Drug: Enteric coated
Normalized name: Mesasal Enteric Coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coated 500 mg 5-ASA tablets administered after standard meals
Study: 1550697
Drug: Enteric coated
Normalized name: Mesasal Enteric Coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coated 500 mg 5-ASA tablets administered 1 h before meals
Study: 3862607
Drug: 0.6 g
Normalized name: Ceo-Two, 0.9 g-0.6 g rectal suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 g oral N‐acetylcysteine/day for 60 days
Study: 31919558
Drug: Oral iron(II)
Normalized name: iron(II) sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron(II)
Study: 16836708
Drug: Cocaine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (40 mg)
Study: 23958375
Drug: Sunitinib (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (37.5 mg/day)
Study: 23958375
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care (SOC) chemotherapy
Study: 11696046
Drug: Grass pollen
Normalized name: grass pollen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grass pollen immunotherapy (IT)
Study: 11696046
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (PL)
Study: 9385883
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy for acute myocardial infarction in patients with diabetes
Study: 9385883
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy for acute myocardial infarction in patients without diabetes
Study: 8201614
Drug: Delayed control
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed control group (no immediate treatment)
Study: 2510660
Drug: labetalol (L)
DrugBank: Labetalol (DB00598)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: labetalol (L)
Study: 3067303
Drug: labetalol (L)
DrugBank: Labetalol (DB00598)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: labetalol (L) and captopril (C)
Study: 30926396
Drug: Nasal dilator
Normalized name: nasal dilator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal dilator (placebo) treatment
Study: 23218699
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg intravitreal aflibercept (IAI 2Q4)
Study: 23218699
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg intravitreal aflibercept (IAI 2Q4 + PRN)
Study: 21774626
Drug: Open patch
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open patch test with 1% SLS
Study: 21774626
Drug: Open patch
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open patch test with 1% SLS + PT with 0.5% SLS (SLSPT)
Study: 21774626
Drug: CONTROL (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: CONTROL (no treatment)
Study: 11742432
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg po bid
Study: 11742432
Drug: Azithromycin 1200
Normalized name: azithromycin 1200 MG per 30 ML Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 1200 mg po weekly
Study: 8237310
Drug: Beveled margins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beveled margins of cavity preparations
Study: 8237310
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of etched butt-joint cavities with NPG-GMA/ethanol, re-etching, and surface coating with low viscous resin
Study: 27378556
Drug: Hyaluronan (HY)
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyaluronan (HY) injections
Study: 27378556
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (control) injection
Study: 11774933
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 mg tablet dissolved in water)
Study: 9269706
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 mg/day fixed dose or titrated up to 40 mg/day)
Study: 20486463
Drug: Liquor carbonis
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liquor carbonis distillate (LCD) solution 15%
Study: 20486463
Drug: Calcipotriene cream
Normalized name: Calcipotriene Cream
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcipotriene cream 0.005%
Study: 16061591
Drug: Dexamethasone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.5 mg/kg per day for 1 week)
Study: 12352275
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day hydroxychloroquine
Study: 12352275
Drug: Open treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open treatment with hydroxychloroquine
Study: 6367245
Drug: acebutolol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: acebutolol (400 mg/day)
Study: 6367245
Drug: prazosin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: prazosin (4 mg/day)
Study: 6367245
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of prazosin and acebutolol
Study: 30481269
Drug: Trivalent, Russian-backbone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent, Russian-backbone, live, attenuated influenza vaccine (LAIV)
Study: 24118165
Drug: Active magnetic
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active magnetic stimulation (25-min sessions, twice a week, 560 mT peak at 10 Hz)
Study: 23077532
Drug: PCV7 (2-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV7 (2-dose group)
Study: 23077532
Drug: PCV7 (2+1-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV7 (2+1-dose group)
Study: 19721018
Drug: Mediterranean-style diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean-style diet (<50% of daily calories from carbohydrates) (n = 108)
Study: 19721018
Drug: Low-fat diet
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat diet (<30% of daily calories from fat) (n = 107)
Study: 15224630
Drug: Budesonide aqueous
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide aqueous nasal spray (BANS) 128 micrograms b.i.d. for 20 weeks
Study: 11295925
Drug: Immunotherapy (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (combined results)
Study: 11295925
Drug: Immunotherapy (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (with complete resolution)
Study: 9508171
Drug: ABVD plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABVD plus low-dose regional (extended-field) radiation therapy (EF RT)
Study: 3078521
Drug: Pirenzepine 50
Normalized name: pirenzepine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 50 mg daily (n = 200)
Study: 3078521
Drug: Ranitidine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 200 mg daily (n = 200)
Study: 28298397
Drug: Predictive model
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predictive model using clinical variables (age, BMI, Epworth sleepiness scale, peak troponin levels, use of calcium antagonists)
Study: 23545907
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A (salicylic acid, capryloyl salicylic acid, HEPES, glycolic acid, citric acid, dioic acid)
Study: 23545907
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B (BenzaClin®, clindamycin 1% and benzoyl peroxide 5% gel)
Study: 20688209
Drug: In-lab 600-mg
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-lab 600-mg clopidogrel loading dose
Study: 20688209
Drug: Routine 6-h
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine 6-h pre-load with 600-mg clopidogrel
Study: 16629428
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (neurophysiologically based physiotherapy and aerobic training)
Study: 1430670
Drug: Imipramine (200-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (200-300 mg daily)
Study: 4046836
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg/twice daily)
Study: 31183921
Drug: Eriomin 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eriomin 200 mg
Study: 31183921
Drug: Eriomin 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eriomin 400 mg
Study: 31183921
Drug: Eriomin 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eriomin 800 mg
Study: 30531444
Drug: Isoflavone (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone (150 mg dry extract of glycine max) plus probiotics (Lactobacillus acidophilus, Lactobacillus casei, Lactococcus lactis, Bifidobacterium bifidum, and Bifidobacterium lactis)
Study: 30531444
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (1 mg estradiol and 0.5 mg norethisterone acetate)
Study: 30531444
Drug: Isoflavone (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone (150 mg dry extract of glycine max)
Study: 22765856
Drug: Topical diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diltiazem (2 mL of 2%)
Study: 22765856
Drug: Topical nitroglycerine
Normalized name: nitroglycerin Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nitroglycerine (2 mL of 0.2%)
Study: 17315409
Drug: 32 mg
Normalized name: caffeine 32 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 mg sublingual BUP over one hour (one-day group)
Study: 17315409
Drug: 32 mg
Normalized name: caffeine 32 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 mg sublingual BUP over three days (three-day group)
Study: 31601585
Drug: Ward-based Goal-Directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ward-based Goal-Directed Fluid Therapy (GDFT)
Study: 26079842
Drug: Monthly home
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly home counseling visits by community support agents
Study: 20852001
Drug: Amlodipine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine + Valsartan + HCTZ (triple combination)
Study: 20852001
Drug: Valsartan +
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan + HCTZ (dual combination)
Study: 20852001
Drug: Amlodipine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine + Valsartan (dual combination)
Study: 20852001
Drug: Amlodipine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine + HCTZ (dual combination)
Study: 19828902
Drug: Green plantain-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green plantain-based diet (50 g/L)
Study: 16731387
Drug: Immediate placement
Normalized name: IR DIP 10 1 % Iodine Replacement Teat Dip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate placement of Frialit‐2 Synchro implants (IP) after extraction
Study: 16731387
Drug: Delayed placement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed placement of Frialit‐2 Synchro implants (DP) after a 3‐month healing period
Study: 16731387
Drug: Both IP
Normalized name: IP-2018
DrugBank: IP-2018 (DB19049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both IP and DP implants
Study: 8342439
Drug: 45 mg
Normalized name: lutein 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg of immediate‐release oral morphine tablets
Study: 3554084
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg X 1 dose of metoclopramide (regimen A)
Study: 3554084
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg X 2 doses of metoclopramide (regimen B)
Study: 30203123
Drug: Single escalating
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single escalating doses of RN909 (0.3 to 6 mg/kg SC, or 1 mg/kg IV)
Study: 30203123
Drug: Multiple escalating
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple escalating doses of RN909 (50 to 150 mg SC)
Study: 30203123
Drug: Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of RN909
Study: 30203123
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of RN909
Study: 30203123
Drug: Single and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single and multiple doses of RN909
Study: 24812901
Drug: Qiju Dihuang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qiju Dihuang Pill (QDP) for 2-4 weeks
Study: 24812901
Drug: Qiju Dihuang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qiju Dihuang Pill (QDP)
Study: 24829661
Drug: GERD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GERD treatment prior to surgery
Study: 24829661
Drug: No GERD
Approvals — FDA: no, EMA: no, PMDA: no
Description: No GERD treatment prior to surgery
Study: 21609913
Drug: Manual osteopathic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual osteopathic therapy
Study: 28059912
Drug: Phenol injection
Normalized name: Phenol Injection
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenol injection
Study: 31638594
Drug: Standard patient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard patient education (weekly, basic information)
Study: 26416253
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplement intervention (ONS)
Study: 18971325
Drug: AVN944 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVN944 (doses ranging from 25 to 250 mg)
Study: 18971325
Drug: AVN944 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVN944 (doses > 100 mg)
Study: 18971325
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 doses, one with food and one after fasting)
Study: 11167281
Drug: 0.1% fluorometholone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% fluorometholone acetate (steroid group)
Study: 2842882
Drug: BCAA-enriched solution
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA-enriched solution
Study: 2842882
Drug: Conventional amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional amino acid solution (Control)
Study: 26685122
Drug: Sugammadex 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 4 mg.kg(‐1) (high dose group)
Study: 26685122
Drug: Sugammadex 2
Normalized name: sugammadex 200 MG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 2 mg.kg(‐1) (middle dose group)
Study: 26685122
Drug: Sugammadex 1
Normalized name: sugammadex 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 1 mg.kg(‐1) (low dose group)
Study: 25373320
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (1,000 mg iron)
Study: 16368047
Drug: Transdermal reservoir
Normalized name: RESERVOIR,CADD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal reservoir system (fentanyl transdermal reservoir)
Study: 12889679
Drug: Amitriptyline 25
Normalized name: amitriptyline 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 25 mg/day
Study: 10471635
Drug: aerosolized E25
Normalized name: RHUMAB-E25
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: aerosolized E25 1 mg
Study: 10471635
Drug: aerosolized E25
Normalized name: RHUMAB-E25
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: aerosolized E25 10 mg
Study: 8609344
Drug: L-arginine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (20 g/day for 28 days)
Study: 8609344
Drug: Placebo (vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle syrup in equal amounts)
Study: 2031820
Drug: aminophylline 2
Normalized name: aminophylline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: aminophylline 2 mg kg‐1
Study: 2031820
Drug: flumazenil 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: flumazenil 0.01 mg kg‐1
Study: 2031820
Drug: placebo saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo saline 0.1 ml kg‐1
Study: 29912679
Drug: Oral indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral indomethacin (IDC)
Study: 29912679
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen (IB)
Study: 29912679
Drug: Oral indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral indomethacin (IDC) in extremely low-birthweight infants (<1000 g)
Study: 29912679
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen (IB) in extremely low-birthweight infants (<1000 g)
Study: 29912679
Drug: Oral indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral indomethacin (IDC) and Oral ibuprofen (IB)
Study: 24842181
Drug: Targeted intracluster-injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted intracluster-injection (TII) technique
Study: 24842181
Drug: Double-injection (DI)
Normalized name: di-isopropylammonium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-injection (DI) technique
Study: 21638755
Drug: Deferasirox treatment
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferasirox treatment (25 mg/kg/day)
Study: 21638755
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no iron chelation treatment)
Study: 17196682
Drug: Nicorandil (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (4 mg)
Study: 15190527
Drug: CSD implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSD implant plus optimal medical therapy
Study: 7653770
Drug: Droperidol 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 1.25 mg intravenously 20 min prior to the end of surgery and a patient‐controlled analgesia infusion containing morphine 1 mg.ml‐1 and droperidol 0.05 mg.ml‐1
Study: 7653770
Drug: Cyclizine 50
Normalized name: cyclizine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclizine 50 mg by slow intravenous injection 20 min prior to the end of surgery and a patient‐controlled analgesia infusion containing morphine 1 mg.ml‐1 and cyclizine 2 mg.ml‐1
Study: 338024
Drug: Oestradiol, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestradiol, 2 mg
Study: 338024
Drug: Oestriol, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestriol, 1 mg
Study: 29154060
Drug: Cholesfytol® (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesfytol® (1 tablet/day)
Study: 23077975
Drug: True RH
Normalized name: anti-D (rh) immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: True RH (elevated awake or asleep SBP/DBP means while treated with 3 medications, or any patient treated with ≥4 medications)
Study: 20573655
Drug: Naloxone (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (IV injection of two 0.4 mg ampules)
Study: 16533781
Drug: 1,200 mg
Normalized name: lecithin 1,200 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,200 mg orally once daily (arm A)
Study: 16533781
Drug: 1,200 mg
Normalized name: lecithin 1,200 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,200 mg orally twice daily (arm B)
Study: 8463435
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 60 mg diltiazem
Study: 8463435
Drug: Diltiazem 60
Normalized name: DILTIAZEM 60MG 12HR CAP,SA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 60 mg three times a day for 3 days
Study: 8463435
Drug: Diltiazem 60
Normalized name: DILTIAZEM 60MG 12HR CAP,SA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 60 mg three times a day for 6 days
Study: 18313127
Drug: Aspirin 75
Normalized name: aspirin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 75 mg/d
Study: 26661570
Drug: Intravenous neostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous neostigmine (0.5 mg)
Study: 8442622
Drug: Nurse-assisted combination
Normalized name: PAD,NURSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-assisted combination of self-quit training and referral